Testosterone Cypionate and Fertility Suppression: The Biology of Why It Happens

The Hypothalamic-Pituitary-Gonadal Axis: How Normal Testosterone Production Works

Your body manufactures testosterone through a tightly regulated three-tier signaling chain called the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulsatile bursts every 60 to 90 minutes. These pulses signal the anterior pituitary to secrete two gonadotropins: LH and FSH.

LH binds to Leydig cells in the testes and triggers testosterone synthesis. FSH binds to Sertoli cells, the nurse cells of the seminiferous tubules, and drives spermatogenesis. This entire system runs on negative feedback. When circulating testosterone (and its metabolite estradiol) reaches sufficient concentrations, the hypothalamus dampens GnRH pulse frequency, and the pituitary reduces LH and FSH output 1. The result is a self-correcting loop that keeps testosterone between roughly 300 and 1 to 000 ng/dL in healthy adult men.

Intratesticular testosterone (ITT) concentration is the critical variable for sperm production. ITT runs 25 to 100 times higher than serum testosterone 2. Sertoli cells need this extreme local concentration to support the 74-day journey from spermatogonium to mature spermatozoon. Any process that collapses ITT will compromise or halt spermatogenesis.

Why Exogenous Testosterone Cypionate Suppresses Fertility

Injecting testosterone cypionate introduces a supraphysiologic bolus of hormone that the hypothalamus cannot distinguish from endogenous production. The brain reads the elevated serum testosterone and its aromatized estradiol as a signal that the testes are overproducing. GnRH pulse frequency drops. LH and FSH fall to near-undetectable levels, often within two weeks of the first injection 3.

Without LH stimulation, Leydig cells stop synthesizing testosterone locally. ITT plummets by up to 94%, despite serum levels being normal or elevated 2. The exogenous testosterone circulating in the blood does not penetrate the seminiferous tubule microenvironment at concentrations sufficient to sustain spermatogenesis. This is the core paradox: a man on TRT may have a serum testosterone of 800 ng/dL while his intratesticular levels sit at a fraction of what his Sertoli cells require.

Without FSH co-stimulation, Sertoli cells lose the second essential signal for sperm maturation. The combined loss of ITT and FSH creates a dual block. Spermatogenesis slows, stalls, and in many cases stops altogether.

A landmark study by Contraceptive Efficacy of Testosterone-Induced Azoospermia in Normal Men (WHO, 1990) demonstrated that 65% of men receiving 200 mg testosterone enanthate weekly (pharmacokinetically similar to cypionate) achieved azoospermia, and an additional 25% reached severe oligospermia (sperm count below 3 million/mL) within six months 4. Only about 10% maintained residual sperm production. These numbers effectively confirmed that exogenous testosterone acts as a male contraceptive in the majority of users.

The Molecular Cascade: From Receptor Binding to Sperm Arrest

The suppression of spermatogenesis involves several distinct molecular events that unfold over days and weeks. Understanding each step clarifies why recovery is possible but not instantaneous.

Step 1: GnRH suppression. Testosterone and estradiol bind to androgen receptors and estrogen receptors (primarily ERα) in the hypothalamic arcuate nucleus. Kisspeptin neurons, the master regulators of GnRH secretion, are inhibited. A 2010 study in the Journal of Clinical Endocrinology & Metabolism showed that exogenous testosterone reduces kisspeptin gene expression in a dose-dependent manner 5. Without kisspeptin pulses, GnRH neurons go functionally silent.

Step 2: Gonadotropin collapse. LH half-life is approximately 20 minutes; FSH half-life is 3 to 4 hours. Once the pituitary stops receiving GnRH stimulation, circulating gonadotropins decline rapidly. Most men on standard TRT doses show LH and FSH below the assay detection limit by week 3 3.

Step 3: Leydig cell quiescence. Without LH, the steroidogenic acute regulatory protein (StAR) pathway inside Leydig cells shuts down. StAR transports cholesterol into mitochondria for conversion to pregnenolone, the first committed step of testosterone biosynthesis. No LH signal means no StAR upregulation, no pregnenolone, and no local testosterone.

Step 4: Sertoli cell dysfunction. Sertoli cells express both androgen receptors and FSH receptors. They need both ligands for full function. ITT activates androgen receptors on Sertoli cells, driving expression of genes for transferrin, androgen-binding protein, and inhibin B. FSH activates the cAMP-PKA pathway, promoting anti-Müllerian hormone production and supporting the blood-testis barrier. Losing both signals simultaneously impairs tight junctions between Sertoli cells, disrupts the seminiferous tubule microenvironment, and triggers apoptosis of developing germ cells 6.

Step 5: Germ cell arrest. The most sensitive stage of spermatogenesis to androgen withdrawal is meiosis. Primary spermatocytes undergoing the first meiotic division require high local androgen concentrations. When ITT falls, these cells undergo apoptosis. Because a full spermatogenic cycle takes approximately 74 days, the clinical manifestation (falling sperm count) appears gradually. Counts typically reach their nadir at 3 to 4 months after TRT initiation.

Timeline of Suppression and the Dose-Response Relationship

Not all TRT regimens suppress spermatogenesis at the same rate or to the same degree. Dose, injection frequency, and baseline gonadal function all matter.

A study published in Fertility and Sterility followed 66 men starting testosterone cypionate 200 mg intramuscularly every two weeks. Mean sperm concentration fell from 55.8 million/mL to 1.1 million/mL by month 6 7. Forty-three of 66 men (65%) were azoospermic by month 6. The remaining men had counts below 5 million/mL.

Higher doses and more frequent injections produce faster, more complete suppression. Men receiving 100 mg weekly tend to reach azoospermia sooner than those on 200 mg biweekly, likely because weekly dosing maintains steadier serum levels that suppress GnRH more consistently, avoiding the trough-phase partial recovery that biweekly dosing allows. A 2013 review in the Journal of Clinical Endocrinology & Metabolism confirmed that steady-state androgen exposure correlates with more profound gonadotropin suppression 8.

Younger men with strong baseline spermatogenesis may take longer to reach azoospermia. Men with pre-existing oligospermia may become azoospermic within weeks. These individual differences explain why TRT is not reliable as a sole contraceptive: the 10% of men who maintain residual spermatogenesis can still father children.

Testicular Atrophy: The Visible Consequence

Testicular volume is approximately 80% seminiferous tubules by mass. When spermatogenesis ceases and Leydig cells atrophy from disuse, the testes shrink. Men on TRT for 6 months or longer typically experience a 10 to 20% reduction in testicular volume 9. This is often the first clinical sign that a patient or partner notices.

The atrophy is primarily driven by loss of germ cells and Sertoli cell vacuolization, not by irreversible fibrosis (at least in the first 1 to 3 years). This distinction matters for recovery potential: the architectural framework of the seminiferous tubules usually remains intact, allowing repopulation once gonadotropin signaling resumes.

Prolonged suppression beyond 2 to 3 years, particularly at high doses, may lead to more persistent structural changes. One case series from the University of Miami reported that men on TRT for over 4 years had slower and less complete spermatogenic recovery compared to those on therapy for less than 2 years 10.

Managing Fertility While on Testosterone Cypionate

The American Urological Association (AUA) 2018 guidelines state plainly: "Testosterone therapy should not be prescribed to men who desire fertility in the near term" 11. The Endocrine Society echoes this position. For men who need androgen support and want to preserve fertility, several strategies exist.

Human chorionic gonadotropin (hCG). hCG mimics LH. Doses of 500 IU subcutaneously every other day, or 1 to 500 IU three times per week, maintain ITT at roughly 25% of baseline in men concurrently receiving TRT 2. This is often sufficient to sustain low-level spermatogenesis. A study by Coviello et al. showed that 250 IU hCG every other day combined with 200 mg testosterone enanthate weekly maintained ITT above the threshold needed for spermatogenesis in most subjects 2.

Selective estrogen receptor modulators (SERMs). Clomiphene citrate 25 to 50 mg daily stimulates the pituitary to release LH and FSH by blocking estrogen's negative feedback at the hypothalamus. Some clinicians use clomiphene as an alternative to TRT in hypogonadal men who want children. A 2015 study showed that clomiphene maintained sperm counts while raising serum testosterone to the low-normal range in hypogonadal men 12.

FSH supplementation. For men with the most resistant azoospermia during or after TRT, adding recombinant FSH (75 to 150 IU three times weekly) to hCG can reactivate Sertoli cell function. This combination mimics the natural dual-signal environment. Dr. Larry Lipshultz, a pioneer in male reproductive urology, has noted: "The key to reversing TRT-induced azoospermia is restoring both arms of the gonadotropin signal. hCG alone is sometimes insufficient because it does nothing for the FSH-dependent Sertoli cell pathways" 13.

Sperm banking. For men committed to long-term TRT, cryopreservation of sperm before starting therapy provides a guaranteed backup. The AUA recommends discussing sperm banking at the prescribing visit for all men of reproductive age 11.

Recovery After Discontinuation

The Endocrine Society has stated: "Spermatogenesis usually recovers within 6 to 12 months of testosterone discontinuation, though recovery may be slower after prolonged use" 14. A meta-analysis of 30 studies (N=1,549 men) published in Fertility and Sterility found that 67% of men recovered to a sperm concentration of at least 20 million/mL within 6 months, 90% within 12 months, and 100% by 24 months 15.

Recovery follows a predictable sequence. LH and FSH rebound first, often detectable within 1 to 4 weeks of the last injection. ITT rises next, reaching spermatogenesis-supporting concentrations within 4 to 8 weeks. Because a full spermatogenic cycle is 74 days, the first mature sperm do not appear until roughly 3 months after gonadotropin recovery begins.

Factors that slow recovery include:

• Duration of TRT use. Men on therapy for more than 2 years show median recovery times approximately 50% longer than those on therapy for less than 1 year.
• Age. Men over 45 recover more slowly, possibly due to age-related decline in spermatogonial stem cell reserves.
• Prior fertility status. Men with pre-existing varicocele or subclinical Klinefelter mosaicism may not recover fully.
• Concomitant use of nandrolone or other 19-nortestosterone derivatives. These compounds are more profoundly suppressive than testosterone itself and may delay HPG axis recovery by months.

Clinicians often prescribe a recovery protocol: hCG 3 to 000 IU every other day for 4 to 6 weeks, followed by clomiphene 25 mg daily for 2 to 3 months. Semen analyses are checked at 3-month intervals. If azoospermia persists beyond 12 months, the addition of recombinant FSH should be considered 10.

Why Some Men Are More Susceptible Than Others

Genetic variation in the androgen receptor (AR) CAG repeat length partly explains why some men experience complete azoospermia on low-dose TRT while others maintain oligospermic counts on high doses. Shorter CAG repeats produce a more sensitive androgen receptor, which amplifies the negative feedback signal to the hypothalamus. A 2006 study in the Journal of Clinical Endocrinology & Metabolism found that men with AR CAG repeat lengths below 20 had significantly greater FSH suppression on exogenous testosterone compared to men with repeats above 24 16.

Body composition also plays a role. Men with higher adiposity aromatize more testosterone to estradiol. Since estradiol is roughly 200 times more potent than testosterone at suppressing GnRH, obese men on TRT may experience faster and more complete gonadotropin shutdown 1.

Clinical Monitoring During TRT

Any man of reproductive age starting testosterone cypionate should have a baseline semen analysis, serum LH, FSH, and testosterone before the first injection. Repeat semen analysis at 3 and 6 months documents the degree of suppression. Testicular ultrasound at baseline and annually tracks volume changes.

If a man on TRT decides he wants to conceive, the treating physician should discontinue exogenous testosterone and initiate a gonadotropin recovery protocol with serial semen analyses every 3 months until counts exceed 15 million/mL with at least 40% progressive motility, the WHO reference values for normal fertility potential 17.